CIK 0001593899 · Non-accelerated filer<br>Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 460574869
- Phone
- (857) 284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Foster Wayne EVP, Chief Accounting Officer | Grant or award | +8,000 | 62,190 | ||
| 2025-01-31 | Foster Wayne EVP, Chief Accounting Officer | Shares withheld for taxes | −12,062 | $3.06 | $37K | 50,128 |
| 2025-01-31 | Foster Wayne EVP, Chief Accounting Officer | Option exercise · Restricted Stock Units | −33,333 | 33,333 | ||
| 2025-01-31 | Foster Wayne EVP, Chief Accounting Officer | Grant or award · Restricted Stock Units | +8,000 | 8,000 | ||
| 2025-01-31 | Foster Wayne EVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +120,100 | 120,100 | ||
| 2025-01-16 | BERGER FRANKLIN M Director | Purchase | +10,000 | $3.36 | $34K | 476,897 |
| 2025-01-16 | BERGER FRANKLIN M Director | Purchase | −10,000 | $3.36 | $34K | 476,897 |
| 2025-01-15 | BERGER FRANKLIN M Director | Purchase | +15,000 | $3.19 | $48K | 466,897 |
| 2025-01-15 | BERGER FRANKLIN M Director | Purchase | −15,000 | $3.19 | $48K | 466,897 |
| 2024-12-10 | BERGER FRANKLIN M Director | Sale | −359,606 | $2.85 | $1.0M | 451,897 |
| 2024-09-19 | Sommadossi Jean-Pierre President, CEO, and Chairman | Sale 10b5-1 | −1,841 | $4.00 | $7K | 5,866,025 |
| 2024-09-18 | Sommadossi Jean-Pierre President, CEO, and Chairman | Sale 10b5-1 | −22,187 | $4.03 | $89K | 5,867,866 |
| 2024-09-17 | Sommadossi Jean-Pierre President, CEO, and Chairman | Sale 10b5-1 | −33,941 | $4.05 | $137K | 5,890,053 |
| 2024-06-21 | Duncan Barbara Gayle Director | Grant or award · Restricted Stock Units | +29,600 | 29,600 | ||
| 2024-06-21 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +41,200 | 41,200 | ||
| 2024-06-21 | BERGER FRANKLIN M Director | Grant or award · Restricted Stock Units | +29,600 | 29,600 | ||
| 2024-06-21 | BERGER FRANKLIN M Director | Grant or award · Stock Option (Right to Buy) | +41,200 | 41,200 | ||
| 2024-06-21 | Adams Jerome M. Director | Grant or award · Restricted Stock Units | +29,600 | 29,600 | ||
| 2024-06-21 | Adams Jerome M. Director | Grant or award · Stock Option (Right to Buy) | +41,200 | 41,200 | ||
| 2024-06-21 | Lucidi Bruno Director | Grant or award · Restricted Stock Units | +29,600 | 29,600 |
Page 7 of 14 · 280 trades